NASDAQ:BVXV BiondVax Pharmaceuticals (BVXV) Stock Forecast, Price & News $1.70 0.00 (0.00%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$1.70▼$1.7850-Day Range$1.72▼$2.1652-Week Range$1.70▼$13.60Volume8,545 shsAverage Volume8,229 shsMarket Capitalization$3.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About BiondVax Pharmaceuticals (NASDAQ:BVXV) StockBiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. It focuses on the flu vaccine candidate that was designed to provide multi-strain and multi-season protection against seasonal and pandemic influenza. The company was founded by Ronald Babecoff and Rami Epstein on July 21, 2003 and is headquartered in Jerusalem, Israel.Read More Receive BVXV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BVXV Stock News HeadlinesJune 3, 2023 | americanbankingnews.comBiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Expected to Earn FY2023 Earnings of ($0.01) Per ShareMay 31, 2023 | americanbankingnews.comBrokers Issue Forecasts for BiondVax Pharmaceuticals Ltd.'s Q2 2023 Earnings (NASDAQ:BVXV)June 3, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 30, 2023 | finance.yahoo.comBVXV: Developing anti-IL-17 NanoAbMay 28, 2023 | americanbankingnews.comBiondVax Pharmaceuticals (NASDAQ:BVXV) Receives New Coverage from Analysts at StockNews.comMay 21, 2023 | americanbankingnews.comStockNews.com Begins Coverage on BiondVax Pharmaceuticals (NASDAQ:BVXV)May 15, 2023 | finanznachrichten.deBiondVax Pharmaceuticals Ltd.: BiondVax Announces First Quarter 2023 Financial Results and Provides Business UpdateMay 15, 2023 | msn.comBiondvax Pharmaceuticals GAAP EPS of $0.00 beats by $0.73June 3, 2023 | Stansberry Research (Ad)The gold catalyst we've waited forBecause even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.May 15, 2023 | finance.yahoo.comBiondVax Announces First Quarter 2023 Financial Results and Provides Business UpdateApril 26, 2023 | americanbankingnews.comBiondVax Pharmaceuticals (NASDAQ:BVXV) Now Covered by Analysts at StockNews.comApril 20, 2023 | theglobeandmail.comBiondVax Pharmaceuticals (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership TeamApril 19, 2023 | americanbankingnews.comBiondVax Pharmaceuticals (NASDAQ:BVXV) Coverage Initiated at StockNews.comApril 18, 2023 | finanznachrichten.deBiondVax Pharmaceuticals Ltd.: BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business UpdateApril 4, 2023 | marketwatch.comBioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing TherapiesMarch 26, 2023 | marketwatch.comBioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 VariantsMarch 25, 2023 | americanbankingnews.comBiondVax Pharmaceuticals (NASDAQ:BVXV) Coverage Initiated by Analysts at StockNews.comMarch 16, 2023 | finance.yahoo.comBiondVax to Present at BIO-Europe SpringMarch 6, 2023 | finance.yahoo.comIBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir ReichmanMarch 3, 2023 | finance.yahoo.comIBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research InstitutesFebruary 2, 2023 | finance.yahoo.comBiondVax Presenting at BIO CEO & Investor ConferenceJanuary 25, 2023 | benzinga.comBioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical StudyJanuary 25, 2023 | benzinga.comBiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19January 23, 2023 | markets.businessinsider.comBiondVax Pharma: In Vivo Data Shows NanoAb Virtually Prevents COVID-19 In HamstersJanuary 23, 2023 | finance.yahoo.comBiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment CandidateJanuary 23, 2023 | it.tmcnet.comBiondVax's Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo StudyJanuary 23, 2023 | finance.yahoo.comBiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo StudySee More Headlines BVXV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BVXV Company Calendar Last Earnings4/17/2023Today6/03/2023Next Earnings (Estimated)8/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BVXV CUSIPN/A CIK1611747 Webwww.biondvax.com Phone9723029302529Fax972-8930-2531Employees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-346.36% Return on Assets-28.48% Debt Debt-to-Equity Ratio5.92 Current Ratio4.28 Quick Ratio4.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.58) per share Price / Book-0.67Miscellaneous Outstanding Shares1,870,000Free Float1,755,000Market Cap$3.22 million OptionableNot Optionable Beta2.47 Key ExecutivesAmir ReichmanChief Executive Officer & DirectorElad MarkChief Operating OfficerUri Ben-OrChief Financial OfficerTamar Ben-YedidiaChief Science OfficerDalit Weinstein FischerHead-Technical, Research & DevelopmentKey CompetitorsFresh Tracks TherapeuticsNASDAQ:FRTXKiromic BioPharmaNASDAQ:KRBPBrookline Capital AcquisitionNASDAQ:BCACPolarityTENASDAQ:PTERubius TherapeuticsNASDAQ:RUBYView All CompetitorsInstitutional OwnershipSabby Management LLCBought 105,412 shares on 5/16/2023Ownership: 17.450%View All Institutional Transactions BVXV Stock - Frequently Asked Questions How have BVXV shares performed in 2023? BiondVax Pharmaceuticals' stock was trading at $2.96 at the start of the year. Since then, BVXV stock has decreased by 41.9% and is now trading at $1.72. View the best growth stocks for 2023 here. Are investors shorting BiondVax Pharmaceuticals? BiondVax Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 18,000 shares, an increase of 20.8% from the April 30th total of 14,900 shares. Based on an average trading volume of 27,000 shares, the short-interest ratio is presently 0.7 days. View BiondVax Pharmaceuticals' Short Interest. When is BiondVax Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 24th 2023. View our BVXV earnings forecast. How were BiondVax Pharmaceuticals' earnings last quarter? BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) released its quarterly earnings results on Monday, April, 17th. The company reported ($0.30) earnings per share for the quarter. When did BiondVax Pharmaceuticals' stock split? BiondVax Pharmaceuticals's stock reverse split before market open on Friday, November 25th 2022. The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of BiondVax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA). When did BiondVax Pharmaceuticals IPO? (BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at a price of $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO. What is BiondVax Pharmaceuticals' stock symbol? BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV." Who are BiondVax Pharmaceuticals' major shareholders? BiondVax Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Sabby Management LLC (17.45%). How do I buy shares of BiondVax Pharmaceuticals? Shares of BVXV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BiondVax Pharmaceuticals' stock price today? One share of BVXV stock can currently be purchased for approximately $1.72. How much money does BiondVax Pharmaceuticals make? BiondVax Pharmaceuticals (NASDAQ:BVXV) has a market capitalization of $3.22 million. The company earns $-5,800,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis. How can I contact BiondVax Pharmaceuticals? BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The official website for the company is www.biondvax.com. The company can be reached via phone at 9723029302529, via email at j.phillipson@biondvax.com, or via fax at 972-8930-2531. This page (NASDAQ:BVXV) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiondVax Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.